Feb 16 |
Prelude Therapeutics GAAP EPS of -$2.02 in-line
|
Feb 15 |
Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024
|
Feb 5 |
Prelude Therapeutics: Interesting Pipeline That Is Too Early To Warrant My Buy
|
Feb 3 |
Prelude Therapeutics: Scientifically Interesting Oncology Company With Preclinical Data
|
Jan 14 |
Prelude Therapeutics Incorporated (NASDAQ:PRLD) is definitely on the radar of hedge funds investors who own 33% of the company
|
Jan 2 |
Shell (SHEL) Resumes LNG Loading From Prelude Facility
|
Dec 11 |
Prelude Therapeutics looks to raise $25M through a private placement
|
Dec 11 |
Prelude Therapeutics Announces $25 Million Private Placement
|
Nov 28 |
Shell's (SHEL) Prelude LNG Facility to Restart in December
|